Enbrel® in Psoriatic Arthritis

Amgen

Overview

This study is testing the effect of etanercept in treating both the skin and joint symptoms of psoriatic arthritis patients. Enbrel®, also known as etanercept, has already been approved by the Federal Food Drug Administration for the treatment of psoriatic arthritis. It is taken as an injection under the skin. Participants in the trial will be offered etanercept free of charge to be self-injected once weekly for 24 weeks. During that period they will have 5 appointments at the study center and will also be asked to complete assessments of their health.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Psoriasis

Interventions

Enbrel®DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Individuals may be eligible to enroll in this study if they suffer from psoriasis (covering at least 10% of the body), and: - have had two or more swollen, tender or painful joints for at least 3 months or: - have lower back pain which your physician has diagnosed as sacroiliitis or spondylitis in one or more joints or: - have been diagnosed with active psoriatic arthritis

Outcomes

Primary Outcomes

The proportion of subjects achieving a status on the Physician Global Assessment of Psoriasis of ""mild"" or better at week 24.

Secondary Outcomes

Quality of life and disability as measured by the DLQI and HAQ

Financial impact of therapy on disease as measured by Patient Pharmacoeconomic Questionnaire

Serious Adverse Events

Patient Global Assessment of Psoriasis

Patient Global Assessment of Joint Disease

Patient Global Assessment of Joint Pain

Patient Assessment of Morning Stiffness Duration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.